Egon Pfarr

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Skeletal Muscle

Cardiovascular Disease

Randomized Controlled Trial

Top Venues

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, Gerasimos S Filippatos, James L Januzzi, Carolyn Su Ping Lam, Naveed Sattar, Egon Pfarr, Matias Nordaby, Martina Brueckmann, Stuart J Pocock, Faiez Zannad, Milton Packer
Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled. Circulation (2022)
Stefan D Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle J Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Audrey Koitka-Weber, Martina Brueckmann, JoAnn Lindenfeld, William T Abraham, null null
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation 144 (15) (2021)